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Stevens-Johnson syndrome (SJS) and drug-induced
hypersensitivity syndrome (HSS, also known as DRESS)
are life-threatening drug hypersensitivity reactions.
Previous studies on genetic predictors for SJS and HSS
were focused on immune-related genes and on known,
frequent polymorphisms in the genome. For the antic-
onvulsant carbamazepine (CBZ), genetic markers for
CBZ-induced SJS and HSS have been identified in the
HLA region (HLA-B*15:02, HLA-A*31:01). However,
many patients carriyng HLA-B*15:02 or HLA-A*31:01
tolerate CBZ, resulting in a low positive predictive value
of a predictive test based on these genetic markers
alone. In this pilot study, we aimed to identify rare
genetic variants potentially associated with CBZ-induced
SJS and HSS using whole exome sequencing in seven
children with CBZ-induced SJS and five children with
CBZ-induced HSS. Whole exome sequencing was per-
formed using Illumina TruSeq exome capture and
sequencing technology. Paired-end sequence reads were
aligned and variants within 150 bp of the 64 Mb target
region were identified using Bowtie, BWA and GATK.
DNA samples from 95 CBZ-tolerant Canadian children
were pooled and sequenced to a median depth of 300-
fold to estimate frequencies of sequence variants identi-
fied in the hypersensitivity cases. All study participants
were recruited through the Canadian Pharmacogenomics
Network for Drug Safety. Children with CBZ-induced SJS
or HSS were of European, Asian and First Nations ances-
try with three SJS cases of Asian origin carrying HLA-
B*15:02 and two HSS patients of European and First
Nations origin carrying HLA-A*31:01. No individual rare
single nucleotide variant (SNV) was strongly overrepre-
sented in the SJS or HSS cases either in combined or in
hypersensitivity reaction-specific analyses. Gene-based
analyses revealed several candidate genes with rare non-
synonymous SNVs observed in a majority of SJS or HSS
cases, respectively, which require follow-up in additional
patients. With a hypothesis-free, comprehensive genetic
screening approach, we identified new candidate genes
and variants potentially involved in the development of
CBZ-induced SJS or HSS for further investigation. The
identified genes and pathways may lead to novel hypoth-
eses for the pathomechanisms of these serious dermatolo-
gic reactions, potentially opening up new possibilities for
prevention and treatment strategies.
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